San Diego-primarily based Viking Therapeutics marked alone as a significant competitor in the weight loss drug market place in February just after revealing promising details from the mid-phase demo of experimental drug VK2735, which advised it rivaled—and outperformed—Novo and Lilly drugs when presented to be a weekly injection As well as in M